Related Experiment Videos
Clinical aspects of human immunodeficiency virus-related lymphoma.
C F von Gunten1, J H Von Roenn
1Northwestern University, Chicago, Illinois.
Current Opinion in Oncology
|October 1, 1992
Summary
The incidence of non-Hodgkin's lymphoma (NHL) has increased in patients with human immunodeficiency virus (HIV) due to longer lifespans. Prognosis is influenced by factors like performance status and bone marrow involvement, with central nervous system lymphoma showing poor outcomes.
Area of Science:
- Oncology
- Infectious Diseases
- Immunology
Background:
- Improved antiretroviral therapy and prophylaxis have increased survival for patients with human immunodeficiency virus (HIV).
- This increased longevity has led to a higher incidence of non-Hodgkin's lymphoma (NHL) in the HIV-infected population.
- The risk of NHL correlates inversely with CD4 count, a key indicator of immune suppression.
Purpose of the Study:
- To review the epidemiology, presentation, prognostic factors, and treatment of non-Hodgkin's lymphoma in HIV-infected patients.
- To highlight challenges in managing NHL in immunocompromised individuals.
- To discuss recent therapeutic advancements and their impact on survival.
Main Methods:
- Literature review of studies on HIV-associated non-Hodgkin's lymphoma.
- Analysis of clinical presentation, risk factors, and treatment outcomes.
- Evaluation of prognostic indicators and therapeutic strategies.
Main Results:
- HIV-associated NHL incidence is rising with improved HIV management.
- Patients often present with advanced, extranodal disease, with the central nervous system being a common site (10-20% of cases).
- Key prognostic factors include performance status, prior acquired immunodeficiency syndrome (AIDS) diagnosis, and bone marrow involvement.
Conclusions:
- Therapy for NHL in HIV patients is complex due to immunosuppression, opportunistic infections, and poor bone marrow reserve.
- While progress has been made with colony-stimulating factors and less intensive chemotherapy for systemic NHL, radiation therapy for primary central nervous system lymphoma has not improved survival.